NO970374L - New connections - Google Patents

New connections

Info

Publication number
NO970374L
NO970374L NO970374A NO970374A NO970374L NO 970374 L NO970374 L NO 970374L NO 970374 A NO970374 A NO 970374A NO 970374 A NO970374 A NO 970374A NO 970374 L NO970374 L NO 970374L
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO970374A
Other languages
Norwegian (no)
Other versions
NO970374D0 (en
Inventor
Michael Joseph Browne
Kay Elizabeth Murphy
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Peter Ronald Young
Allan Richard Shatzman
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415379A external-priority patent/GB9415379D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO970374D0 publication Critical patent/NO970374D0/en
Publication of NO970374L publication Critical patent/NO970374L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO970374A 1994-07-29 1997-01-28 New connections NO970374L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415379A GB9415379D0 (en) 1994-07-29 1994-07-29 Novel compounds
US46829795A 1995-06-06 1995-06-06
PCT/EP1995/003036 WO1996004388A1 (en) 1994-07-29 1995-07-28 Novel compounds

Publications (2)

Publication Number Publication Date
NO970374D0 NO970374D0 (en) 1997-01-28
NO970374L true NO970374L (en) 1997-02-19

Family

ID=26305369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970374A NO970374L (en) 1994-07-29 1997-01-28 New connections

Country Status (13)

Country Link
EP (1) EP0770135A1 (en)
JP (1) JPH10503371A (en)
CN (1) CN1117155C (en)
AU (1) AU3382595A (en)
BR (1) BR9508469A (en)
CA (1) CA2196200A1 (en)
CZ (1) CZ25697A3 (en)
HU (1) HUT76369A (en)
MX (1) MX9700764A (en)
NO (1) NO970374L (en)
NZ (1) NZ292124A (en)
PL (1) PL182665B1 (en)
WO (1) WO1996004388A1 (en)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6287801B1 (en) * 1996-07-22 2001-09-11 Smithkline Beecham Corporation Nucleic acids encoding the G-protein coupled receptor HNFDS78
AU5606098A (en) * 1996-12-20 1998-07-17 Amgen, Inc. Ob fusion protein compositions and methods
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
JP2002506625A (en) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Cytokine receptor common γ chain-like
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
ES2609016T3 (en) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Antibodies that bind immunospecifically to BLyS
JP4434580B2 (en) 2000-11-28 2010-03-17 メディミューン，エルエルシー Methods for administering / prescribing anti-RSV antibodies for prevention and treatment
DK1355919T3 (en) 2000-12-12 2011-03-14 Medimmune Llc Molecules with longer half-lives, compositions and uses thereof
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
ATE470858T1 (en) * 2001-02-22 2010-06-15 Univ New York State Res Found OPIATOR RECEPTORS
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002257142B2 (en) 2001-04-13 2008-09-04 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
AU2003276832A1 (en) 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
PT1534335E (en) 2002-08-14 2012-02-28 Macrogenics Inc Fcgammariib-specific antibodies and methods of use thereof
JP2006517962A (en) * 2003-01-18 2006-08-03 チルドレンズ ホスピタル メディカル センター Regulation of genes induced by allergens
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
JP5356648B2 (en) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
MXPA05013564A (en) * 2003-06-12 2006-03-09 Lilly Co Eli Fusion proteins.
SI1641823T1 (en) 2003-06-12 2011-12-30 Lilly Co Eli Glp-1 analog fusion proteins
JP4934426B2 (en) 2003-08-18 2012-05-16 メディミューン，エルエルシー Antibody humanization
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
JP2007517506A (en) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション Targeting compounds
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
ATE444306T1 (en) * 2004-05-13 2009-10-15 Lilly Co Eli FGF-21 FUSION PROTEINS
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
DK1871418T3 (en) 2005-04-19 2014-06-10 Seattle Genetics Inc Humanized anti-CD70 binding agents and uses thereof
CA2607588A1 (en) 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
DK2041576T3 (en) 2006-06-21 2011-12-05 Apogenix Gmbh Differential cytokine expression in human cancers
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
JP2010506842A (en) 2006-10-16 2010-03-04 メディミューン，エルエルシー Molecules with reduced half-life, compositions thereof and uses
DK2099823T4 (en) 2006-12-01 2022-05-09 Seagen Inc Target binding agent variants and uses thereof
WO2008121616A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles
US10280211B2 (en) 2007-05-04 2019-05-07 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
KR101588061B1 (en) 2007-05-14 2016-01-25 메디뮨 엘엘씨 Methods of reducing eosinophil levels
NO2796466T3 (en) 2007-12-07 2018-04-21
CN102083460A (en) 2008-01-18 2011-06-01 米迪缪尼有限公司 Cysteine engineered antibodies for site-specific conjugation
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101030978B1 (en) * 2008-07-10 2011-04-28 (주) 에이프로젠 Recombinant Expression Vectors for Animal Cells
EP2815766B1 (en) 2008-08-05 2017-07-05 Novartis AG Compositions and methods for antibodies targeting complement protein C5
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
BRPI1016204A2 (en) 2009-04-22 2016-04-19 Merck Patent Gmbh antibody fusion proteins with modified fcrn binding sites
DK2437767T3 (en) 2009-06-01 2015-09-28 Medimmune Llc MOLECULES WITH EXTENDED half-lives and uses thereof
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
MX2012001882A (en) 2009-08-13 2012-04-11 Crucell Holland Bv Antibodies against human respiratory syncytial virus (rsv) and methods of use.
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
JP2013527762A (en) 2010-05-06 2013-07-04 ノバルティス アーゲー Therapeutic low density lipoprotein related protein 6 (LRP6) antibody compositions and methods of use
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
SG10201505218YA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Factor ix polypeptides and methods of use thereof
TWI539963B (en) 2010-07-09 2016-07-01 庫賽爾荷蘭公司 Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013004012B1 (en) 2010-08-20 2021-03-23 Novartis Ag ISOLATED MONOCLONAL ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THE SAME TO THE HER3 RECEPTOR, ITS USE AND PHARMACEUTICAL COMPOSITION
EP2608807A1 (en) 2010-08-27 2013-07-03 Stem Centrx, Inc. Notum protein modulators and methods of use
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2758422A1 (en) 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Modified albumin-binding domains and uses thereof to improve pharmacokinetics
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
CN104053671A (en) 2011-11-01 2014-09-17 生态学有限公司 Antibodies and methods of treating cancer
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
RS62689B1 (en) 2011-11-04 2021-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
KR20140091031A (en) 2011-11-04 2014-07-18 노파르티스 아게 Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
SG11201402783YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EA201491107A1 (en) 2011-12-05 2014-11-28 Новартис Аг ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CN108383909B (en) 2012-02-24 2021-08-24 艾伯维施特姆森特克斯有限责任公司 anti-SEZ 6 antibodies and methods of use
AU2013203459B2 (en) 2012-02-24 2016-11-03 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
BR112015001459B1 (en) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc ISOLATED ANTIBODY OR FRAGMENT THEREOF, CONJUGATE, USES THEREOF, PHARMACEUTICAL COMPOSITION, POLYNUCLEOTIDE, VECTOR, HOST CELL, ISOLATED CELL, KIT, IN VITRO METHOD TO INHIBIT KIT ACTIVITY, METHOD TO PRODUCE AN ANTIBODY
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
MX368067B (en) 2012-12-05 2019-09-18 Novartis Ag Compositions and methods for antibodies targeting epo.
UY35195A (en) 2012-12-18 2014-07-31 Novartis Ag COMPOSITIONS AND METHODS FOR PROLINED ACTION PROTEINS
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
PT2970473T (en) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CN103265637B (en) * 2013-06-04 2015-10-21 江苏众红生物工程创药研究院有限公司 A kind of Recombinant Swine IL-4-Fc fusion rotein and encoding gene thereof and expression method
JP6824735B2 (en) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン Anti-C10orf54 antibody and how to use it
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
UY35620A (en) 2013-06-21 2015-01-30 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
KR20160054501A (en) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 Nucleic acids encoding human antibodies to sialyl-lewis a
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
BR112016004245A2 (en) 2013-08-28 2017-10-17 Stemcentrx Inc sez6 modulators and methods of use
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
MY191944A (en) 2014-01-24 2022-07-20 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
CR20160437A (en) 2014-02-21 2017-02-20 Abbvie Stemcentrx Llc CONJUGATES OF ANTI-DROSOPHILA ANTIBODIES SIMILAR TO DELTA 3 (ANTI-DLL3) AND MEDICINES FOR USE IN THE TREATMENT AGAINST MELANOMA
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
ES2913205T3 (en) 2014-05-13 2022-06-01 Bioatla Inc Conditionally active biological proteins
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
KR102614642B1 (en) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 Human monoclonal antibodies to ganglioside gd2
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
PL3177642T3 (en) 2014-08-07 2022-03-07 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017002805A (en) 2014-09-03 2017-12-20 Bioatla Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts.
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
PL3800202T3 (en) 2014-12-11 2023-06-12 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
WO2016193872A2 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
UY36889A (en) 2015-09-09 2017-04-28 Novartis Ag MOLECULES OF JOINT TO TIMICA STROMAL LYMPHOPOYETIN (TSLP) AND METHODS OF USE OF THE MOLECULES
RS61763B1 (en) 2015-09-09 2021-05-31 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MX2018003689A (en) 2015-09-29 2018-04-30 Celgene Corp Pd-1 binding proteins and methods of use thereof.
AU2016350613B2 (en) 2015-11-02 2023-10-05 Bioatla, Llc Conditionally active polypeptides
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
CN108697799A (en) 2016-03-22 2018-10-23 生态学有限公司 The application of anti-LGR5 monoclonal antibodies
CN109071647B (en) 2016-04-27 2022-11-22 诺华股份有限公司 Anti-growth differentiation factor 15 antibody and application thereof
TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
CN110381988A (en) 2016-06-15 2019-10-25 诺华股份有限公司 Use the method for the inhibitor for treating disease of Bone Morphogenetic Protein 6 (BMP6)
EP3481866B1 (en) 2016-07-06 2024-07-24 Bristol-Myers Squibb Company Combination of tim-4 antagonist and pd-1 antagonist and methods of use
KR102257154B1 (en) 2016-09-19 2021-05-28 셀진 코포레이션 Methods of treating immune diseases using PD-1 binding protein
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018116255A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
JP7110199B2 (en) 2016-12-23 2022-08-01 ノバルティス アーゲー Methods of treatment with anti-factor XI/XIa antibodies
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
CN111107868A (en) 2017-05-24 2020-05-05 诺华股份有限公司 Antibody cytokine transplantation proteins and methods of use
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN112004558A (en) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
CU20210096A7 (en) 2019-05-21 2022-06-06 Novartis Ag CD19 BINDING MOLECULES
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
EP4143236A1 (en) 2020-05-01 2023-03-08 Novartis AG Engineered immunoglobulins
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
JP2024502832A (en) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド Binding agent molecules with high affinity and/or specificity and methods for their production and use
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
AU2023206045A1 (en) 2022-01-07 2024-08-22 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins.
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR900005995A (en) * 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
DK0835939T3 (en) * 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusion proteins with proportions of immunoglobulin, their preparation and use
DE4137333A1 (en) * 1991-11-13 1993-05-19 W Prof Dr Sebald THERAPEUTIC AGENTS THAT ARE ANTAGONISTS OR PARTIAL AGONISTS OF THE HUMAN INTERLEUKIN 4 OR CONTAIN THEM, HIL-4-MUTANT PROTEINS AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
PL318380A1 (en) 1997-06-09
CN1117155C (en) 2003-08-06
WO1996004388A1 (en) 1996-02-15
CN1164872A (en) 1997-11-12
HUT76369A (en) 1997-08-28
JPH10503371A (en) 1998-03-31
CA2196200A1 (en) 1996-02-15
NZ292124A (en) 1998-10-28
NO970374D0 (en) 1997-01-28
PL182665B1 (en) 2002-02-28
AU3382595A (en) 1996-03-04
EP0770135A1 (en) 1997-05-02
MX9700764A (en) 1997-05-31
BR9508469A (en) 1997-09-16
CZ25697A3 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
NO970374L (en) New connections
NO973231D0 (en) New connections
NO960472D0 (en) New connections
NO20000312D0 (en) New connections
NO303016B1 (en) New connections
NO20002787D0 (en) New connections
FI955927A (en) Substituted 1H-imidazoles
NO970512D0 (en) Novel heteroaryl-oxazolidinones
NO20001938D0 (en) New aryloxy-alkyl-dialkylamines
NO983356L (en) New 19-nor-derivative derivatives
DE69534718D1 (en) SUBSTITUTED 9-ALKYLADENINE
FI942119A0 (en) Anordning i en gasblandare
DK0906288T3 (en) New connections
DK0770132T3 (en) New streptogramins
NO960268D0 (en) New dialkoxypyridinylbenzimidazole derivatives
NO990072D0 (en) New connections
BR9509559A (en) Substituted azolylulsolfonylphenyluracils
NO940195L (en) New connections
NO991097D0 (en) New procedures
FI1516U1 (en) Foerpackning Foer i stapel anordnade smaoark
NO983505D0 (en) New phenanthrides
DE59510274D1 (en) SUBSTITUTED BIPHENYLOXAZOLINE
FI1570U1 (en) Instaellbart vinkelstycke Foer central dammsugare
BR7401569U (en) Electro-electronic central
FI1839U1 (en) Larmapparat Foer fast montering i en byggnad

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application